Vispero appoints Indian American executive Sid Gaitonde as CEO to lead the assistive technology firm's next chapter of customer-driven innovation.
Governor Gavin Newsom appoints Los Angeles-based Vishesh Anand as Senior Advisor at California's newly formed Housing and Homelessness Agency.
A blistering rally across Adani Group stocks and the dismissal of a US bribery probe propel Gautam Adani back to the top of Asia's wealth rankings.
Welltower chairman and CEO Shankh Mitra becomes the highest-paid Indian-origin business leader on the planet with an $821.1 million pay package.
Gautam Adani and Mukesh Ambani Together Account for 28% of India's Entire Private Investment — Their AI Data Centres, Green Energy Bets, and Global Ambitions Are Rewriting the Rules of Indian Capitalism
India's Most Admired Technology Company Posts 13.9% Revenue Surge, Signs Landmark AI Deals, and Declares ₹12 Dividend — Proving It Is the Engine of Digital India
India's electric vehicle sales are surging, but charging remains a bottleneck. Battery Smart has built a network that swaps a depleted battery for a fully charged one in under two minutes. Now, with $15 million in fresh debt funding, it is betting that speed and affordability will drive the next wave of EV adoption.
Fresh produce is the hardest part of retail to organise. It is perishable, unpredictable, and resistant to the standard supply-chain economics that FMCG companies use to manage complexity. Ninjacart has spent a decade turning it into a disciplined, technology-enabled, EBITDA-profitable business.
Most precision oncology was built on Western genomic datasets. A genomic profile derived from European ancestry tells you something about a South Asian cancer patient — but not everything, and sometimes not the most important things. 4baseCare was founded to close that gap. OncoTwin, its AI precision oncology platform, was presented at AACR 2026 and selected for the Memorial Sloan Kettering Innovation Hub Challenge.
A PET scan for Alzheimer's diagnosis costs anywhere from ₹40,000 to ₹1,00,000 and requires specialised nuclear medicine facilities that exist in perhaps 50 cities in India. eNLife Research is building the alternative: a blood test that screens for amyloid beta and tau protein biomarkers, delivers results in two to five hours, can be administered at any routine diagnostic centre, and detects the disease up to 15 years before symptoms appear.